Arkolith/Insider Trading/KNSA/Form 4

Ragosa Mark

CHIEF FINANCIAL OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Feb 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$772K
Net Open-Market Flow
-$772K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 9, 2026Sell(S)9K$42.85$391K21K
Feb 9, 2026Sell(S)9K$43.72$382K12K
Feb 9, 2026Option exercise(M)2K$16.90$42K30K
Feb 9, 2026Option exercise(M)8K$12.97$109K27K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 9, 2026Option exercise(M)2K—$00
Feb 9, 2026Option exercise(M)8K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001835458-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML